Pharma

Your Article Summary

See Latest Articles

Salix Pharmaceuticals Announces Statistically Significant Results for Both the Primary and Key Secondary Analyses of Rifaximin in the Treatment of Non–Constipation Irritable Bowel Syndrome in Two Phase 3 Trials
Salix Pharmaceuticals, 09/15/09

Salix Pharmaceuticals, Ltd. announced the successful outcome of two Phase 3, randomized, double–blind, placebo–controlled, multicenter trials, TARGET 1 and TARGET 2, designed to evaluate the efficacy and safety of rifaximin 550 mg TID in the treatment of patients with non–constipation irritable bowel syndrome. In each trial rifaximin versus placebo treated patients demonstrated a statistically significant improvement for the primary endpoint of the adequate relief of IBS symptoms as assessed over one month following completion of a 14–day course of therapy.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09

Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09

 See all of Drug Trials